Sutro Biopharma Inc (STRO) Stock Price, Quote & News

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 881 6500

Fax: 650 553 9659

Website: www.sutrobio.com

Address:

111 Oyster Point Boulevard, South San Francisco, United States

KY3000 Dec. 12 at 11:59 PM

$STRO reformulate 002/003. Sell them.

0 · Reply

KY3000 Dec. 12 at 11:58 PM

$STRO vaxcyte dosed 1st patient, timeclock starts=60$ mill. Astellas IND1st dose 2026. That’s a 15-20$ mill milestone?

0 · Reply

J7263 Dec. 10 at 3:33 AM

$STRO man this pumper on the board is shameless 🤣. No sympathy for those who lost their money on this dumpster fire. What a joke.

0 · Reply

ibaian Dec. 10 at 3:16 AM

$STRO it is trading between 8 to 10 since last six month, it never drop more than 20 % since last 6 months, it can reach to 20 any moment, very strong stock, don’t try to short sell, it is time to buy

0 · Reply

J7263 Dec. 10 at 1:59 AM

$STRO yeah, don't forget the bagholders who bought before the reverse split.

0 · Reply

ibaian Dec. 10 at 12:58 AM

$STRO only 2 million shares with public, will go to 30 $

0 · Reply

ibaian Dec. 10 at 12:57 AM

$STRO 170 million dollar cash, only 2 million shares with public, will be 30 any day thanks

0 · Reply

J7263 Dec. 9 at 11:34 PM

$STRO further dilution to feed piggy management 🐷. Just wait and see. Got to make money somehow.

0 · Reply

ibaian Dec. 8 at 2:57 AM

$STRO low float, heavy cash, 72 % instituions and insiders Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors Sutro Biopharma, Inc.

0 · Reply

KY3000 Dec. 4 at 9:38 AM

$STRO dual payload TKI, step up exel

0 · Reply

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Nov 6, 2025, 4:30 PM EST - 5 weeks ago

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 5, 2025, 4:05 PM EST - 5 weeks ago

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Nov 3, 2025, 8:00 AM EST - 5 weeks ago

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Sep 29, 2025, 5:05 PM EDT - 2 months ago

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Aug 7, 2025, 4:30 PM EDT - 4 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:31 PM EDT - 7 months ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:05 PM EDT - 8 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Apr 28, 2025, 4:05 PM EDT - 8 months ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Mar 15, 2025, 6:40 PM EDT - 9 months ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 14, 2025, 12:09 PM EDT - 9 months ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 13, 2025, 4:07 PM EDT - 9 months ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:05 PM EDT - 9 months ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 3, 2025, 4:05 PM EST - 10 months ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 6:28 PM EST - 1 year ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Nov 13, 2024, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sep 23, 2024, 12:46 PM EDT - 1 year ago

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 20, 2024, 4:01 PM EDT - 1 year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 3, 2024, 10:00 AM EDT - 1 year ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

May 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 5, 2024, 6:31 PM EDT - 1 year ago

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Apr 2, 2024, 6:18 AM EDT - 1 year ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 1:00 AM EDT - 1 year ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jan 4, 2024, 4:05 PM EST - 2 years ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 29, 2023, 4:11 PM EST - 2 years ago

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Dec 14, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

$Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023$

Dec 11, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 4, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Nov 21, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Oct 22, 2023, 4:25 AM EDT - 2 years ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 16, 2023, 4:05 PM EDT - 2 years ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Oct 9, 2023, 9:48 AM EDT - 2 years ago

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 14, 2023, 1:21 PM EDT - 2 years ago

Sutro BioPharma: Good Stewardship Through Early Trials

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Jun 3, 2023, 4:00 PM EDT - 2 years ago

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

May 31, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 15, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

KY3000 Dec. 12 at 11:59 PM

$STRO reformulate 002/003. Sell them.

0 · Reply

KY3000 Dec. 12 at 11:58 PM

$STRO vaxcyte dosed 1st patient, timeclock starts=60$ mill. Astellas IND1st dose 2026. That’s a 15-20$ mill milestone?

0 · Reply

J7263 Dec. 10 at 3:33 AM

$STRO man this pumper on the board is shameless 🤣. No sympathy for those who lost their money on this dumpster fire. What a joke.

0 · Reply

ibaian Dec. 10 at 3:16 AM

0 · Reply

J7263 Dec. 10 at 1:59 AM

$STRO yeah, don't forget the bagholders who bought before the reverse split.

0 · Reply

ibaian Dec. 10 at 12:58 AM

$STRO only 2 million shares with public, will go to 30 $

0 · Reply

ibaian Dec. 10 at 12:57 AM

$STRO 170 million dollar cash, only 2 million shares with public, will be 30 any day thanks

0 · Reply

J7263 Dec. 9 at 11:34 PM

$STRO further dilution to feed piggy management 🐷. Just wait and see. Got to make money somehow.

0 · Reply

ibaian Dec. 8 at 2:57 AM

0 · Reply

KY3000 Dec. 4 at 9:38 AM

$STRO dual payload TKI, step up exel

0 · Reply

makedatbread88 Dec. 3 at 11:12 PM

$STRO recent reverse split brings the float now to 8M Rare to find a penny biotech that has 200 MILLION in cash Interesting down here now post reverse split

0 · Reply

TwongStocks Dec. 3 at 9:45 PM

Today's reverse split results. $STRO 1 for 10. Previous close $.7298, $7.298 split-adjusted Intraday high $8.91 Today's close $8.70 🟢Up 19.21%

0 · Reply

KY3000 Dec. 3 at 9:20 PM

$STRO my app won’t play the call

0 · Reply

gilheydari Dec. 3 at 8:08 PM

$STRO I can not trade on Robinhood, anybody has same problem?

1 · Reply

theBigDollarski Dec. 3 at 2:13 PM

$STRO sold for a loss...now comes the PIPE to dilute existing shareholders further to keep management fat and happy.

0 · Reply

betaino Dec. 3 at 1:27 PM

$STRO https://ir.sutrobio.com/news-events/news-releases/detail/224/sutro-biopharma-announces-first-cohort-of-patients-dosed-in-phase-1-trial-of-stro-004-a-next-generation-tissue-factor-adc-in-tf-expressing-solid-tumors

0 · Reply

TwongStocks Dec. 3 at 11:49 AM

$STRO will reverse split today. Trading is scheduled to resume at 9:00am ET with the RS in effect.

0 · Reply

FreeBeerTomorrow Dec. 3 at 8:24 AM

$STRO Sutro Biopharma, Inc. (STRO) has a reverse stock split scheduled for today, December 3, 2025. Ratio: 1-for-10 reverse stock split. The estimated new float for Sutro Biopharma (STRO) will be approximately 8.5 million shares.

0 · Reply

TwongStocks Dec. 2 at 10:07 PM

I am aware of one NASDAQ reverse split on Wednesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Wednesday morning. $STRO 1 for 10. Will reduce outstanding shares from approx 85.19m to approx 8.52m.

0 · Reply

KY3000 Dec. 2 at 9:06 PM

$STRO 7.30$. 4$ by compliance letter. Dumpster fire

0 · Reply

TwongStocks Dec. 1 at 10:16 PM

$STRO NASDAQ Equity Corporate Actions Alert # 2025 - 645 Information Regarding the Reverse Stock Split and CUSIP Number Change for Sutro Biopharma, Inc. (STRO) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-645 Sutro Biopharma, Inc. (STRO) will effect a one-for-ten (1-10) reverse split of its Common Stock. The reverse stock split will become effective on Wednesday, December 3, 2025. In conjunction with the reverse split, the CUSIP number will change to 869367201.

0 · Reply

DARKP00L Dec. 1 at 5:08 PM

$STRO 12:08 on Dec. 01 2025 Sutro Biopharma shares are trading lower after the company announced a 1-for-10 reverse stock split. #tradeideas

0 · Reply

Market Cap	83.69M
Revenue (ttm)	62.04M
Net Income (ttm)	-227.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-366.63%
Debt to Equity Ratio	0.00

Volume	121,500
Avg Vol	125,845
Day's Range	N/A - N/A
Shares Out	8.51M
Stochastic %K	91%
Beta	1.61
Analysts	Sell
Price Target	$19.00